Using plant virus nanoparticles to improve ovarian cancer treatment
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer
This study is testing a new treatment for high-grade serous ovarian cancer that uses tiny plant-based particles to help your immune system fight cancer and prevent it from coming back after surgery, making sure the treatment is delivered just right for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10896939 on NIH RePORTER |
What this research studies
This research focuses on developing a novel immunotherapy for high-grade serous ovarian cancer (HGSOC) by utilizing plant virus-like nanoparticles (VLPs). These nanoparticles are designed to stimulate the immune system and prevent cancer relapse after surgical treatment. The approach involves creating a biopolymer formulation that combines VLPs with patient-specific tumor antigens to enhance the immune response. The therapy will be administered through a 3D bioprinting technique, allowing for precise delivery and sustained release of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with high-grade serous ovarian cancer who are in remission following surgical treatment.
Not a fit: Patients with other types of ovarian cancer or those who are not in remission may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options that significantly reduce the risk of ovarian cancer relapse.
How similar studies have performed: Similar approaches using immunotherapy and nanoparticles have shown promise in other cancer treatments, indicating potential for success in this novel application.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Steinmetz, Nicole Franziska — University of California, San Diego
- Study coordinator: Steinmetz, Nicole Franziska
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.